Belite Bio (BLTE) Reports FY22, Provides Operational Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. CRWV
2. SPY
3. SLGN
4. EYPT
5. PNB:IN
6. LTM:IN
7. CHRD
8. IRON
9. SLN
10. MANE

Go back to Belite Bio (BLTE) Reports FY22, Provides Operational Highlights

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

March 31, 2023 7:03 PM EDT

12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on April 2542 subjects have been enrolled for the pivotal Phase 3 DRAGON trial evaluating oral tinlarebant in adolescent STGD1; at least 90 subjects are targeted for enrollmentThe first patient of the pivotal Phase 3 PHOENIX trial in Geographic Atrophy (GA) is expected to be enrolled during... More